Security Snapshot

Aldeyra Therapeutics, Inc. - Common Stock (ALDX) Institutional Ownership

CUSIP: 01438T106

13F Institutional Holders and Ownership History from Q2 2014 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

134

Shares (Excl. Options)

38,929,706

Price

$5.18

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Common Stock
Symbol
ALDX on Nasdaq
Shares outstanding
59,794,743
Price per share
$1.69
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
38,929,706
Total reported value
$201,592,852
% of total 13F portfolios
0%
Share change
-387,652
Value change
-$2,038,251
Number of holders
134
Price from insider filings
$1.69
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • ALDX - Aldeyra Therapeutics, Inc. - Common Stock is tracked under CUSIP 01438T106.
  • 134 institutions reported positions in Q4 2025.
  • 1 significant owner is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 134 to 13 between Q4 2025 and Q1 2026.
  • Reported value moved from $201,592,852 to $699,530.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 134 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 01438T106?
CUSIP 01438T106 identifies ALDX - Aldeyra Therapeutics, Inc. - Common Stock in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Aldeyra Therapeutics, Inc. - Common Stock (ALDX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
PERCEPTIVE ADVISORS LLC 7% -19% $17,286,660 -$4,281,484 4,185,632 -20% Perceptive Advisors LLC 31 Dec 2025

As of 31 Dec 2025, 134 institutional investors reported holding 38,929,706 shares of Aldeyra Therapeutics, Inc. - Common Stock (ALDX). This represents 65% of the company’s total 59,794,743 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Aldeyra Therapeutics, Inc. - Common Stock (ALDX) together control 58% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Knoll Capital Management, LLC 9.2% 5,475,516 0% 13% $28,363,172
PERCEPTIVE ADVISORS LLC 7% 4,185,632 -20% 0.4% $21,681,574
BlackRock, Inc. 6.4% 3,850,103 +1.2% 0% $19,943,533
VANGUARD GROUP INC 6.2% 3,698,682 +3% 0% $19,159,173
KINGDON CAPITAL MANAGEMENT, L.L.C. 3.1% 1,850,000 +39% 1.5% $9,583,000
D. E. Shaw & Co., Inc. 2.7% 1,601,324 +16% 0.01% $8,294,858
683 Capital Management, LLC 2.6% 1,530,000 +87% 0.66% $7,925,400
ARDSLEY ADVISORY PARTNERS LP 2.4% 1,450,000 -24% 0.96% $7,511,000
KENNEDY CAPITAL MANAGEMENT LLC 2.1% 1,255,838 +13% 0.14% $6,505,241
AQR CAPITAL MANAGEMENT LLC 2.1% 1,226,922 -18% 0% $6,355,456
GEODE CAPITAL MANAGEMENT, LLC 2% 1,170,537 -0.5% 0% $6,064,616
STATE STREET CORP 1.8% 1,098,600 -0.37% 0% $5,690,748
ACADIAN ASSET MANAGEMENT LLC 1.6% 979,521 +17% 0.01% $5,071,000
JACOBS LEVY EQUITY MANAGEMENT, INC 1.6% 968,751 +2.2% 0.02% $5,018,130
MORGAN STANLEY 1.1% 657,032 -39% 0% $3,403,426
DIMENSIONAL FUND ADVISORS LP 1% 612,258 -5.6% 0% $3,171,391
BANK OF AMERICA CORP /DE/ 0.69% 410,028 +5.1% 0% $2,123,946
NORTHERN TRUST CORP 0.63% 379,405 -7% 0% $1,965,318
WELLS FARGO & COMPANY/MN 0.61% 366,169 +1.3% 0% $1,896,755
RENAISSANCE TECHNOLOGIES LLC 0.59% 350,000 +77% 0% $1,813,000
DEUTSCHE BANK AG\ 0.53% 317,335 +0.83% 0% $1,643,795
GOLDMAN SACHS GROUP INC 0.51% 305,706 +67% 0% $1,583,557
JANE STREET GROUP, LLC 0.51% 303,852 +21% 0% $1,573,954
TWO SIGMA INVESTMENTS, LP 0.48% 287,364 +5.2% 0% $1,488,546
WOODSTOCK CORP 0.45% 266,756 0% 0.12% $1,381,796

Institutional Holders of Aldeyra Therapeutics, Inc. - Common Stock (ALDX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 414,092 $699,530 +$32,692 $1.69 13
2025 Q4 38,929,706 $201,592,852 -$2,038,251 $5.18 134
2025 Q3 39,091,752 $204,002,195 +$26,942,734 $5.22 129
2025 Q2 34,234,495 $131,165,420 -$14,803,182 $3.83 121
2025 Q1 37,522,553 $215,581,662 +$3,357,660 $5.75 124
2024 Q4 37,181,780 $185,566,183 +$2,534,433 $4.99 117
2024 Q3 36,411,204 $196,355,871 +$6,362,230 $5.39 111
2024 Q2 35,332,656 $116,899,840 -$329,270 $3.31 103
2024 Q1 35,411,236 $115,798,928 +$808,753 $3.27 101
2023 Q4 35,121,957 $123,276,317 -$16,780,776 $3.51 103
2023 Q3 37,775,090 $252,308,601 -$9,900,512 $6.68 120
2023 Q2 39,037,773 $327,514,881 +$24,184,461 $8.39 119
2023 Q1 35,585,837 $353,348,951 +$15,344,761 $9.93 107
2022 Q4 34,171,691 $237,833,495 -$18,830,170 $6.96 93
2022 Q3 36,966,565 $197,399,795 +$1,459,079 $5.34 85
2022 Q2 36,943,694 $147,408,805 -$7,357,330 $3.99 88
2022 Q1 38,636,557 $171,807,935 +$10,287,580 $4.44 102
2021 Q4 36,272,402 $145,130,796 -$44,887,818 $4.00 110
2021 Q3 39,720,964 $348,695,759 -$60,891,971 $8.78 114
2021 Q2 45,258,901 $512,794,552 +$153,473,538 $11.33 130
2021 Q1 31,692,851 $376,513,639 +$122,609,589 $11.88 107
2020 Q4 22,091,649 $151,541,784 -$10,169,396 $6.86 95
2020 Q3 23,807,765 $176,308,405 +$68,333,848 $7.41 84
2020 Q2 14,645,367 $61,066,116 -$6,590,170 $4.17 79
2020 Q1 16,769,610 $41,415,535 -$6,410,268 $2.47 69
2019 Q4 17,701,121 $102,840,148 +$1,433,085 $5.81 76
2019 Q3 16,864,477 $88,888,097 -$685,228 $5.27 70
2019 Q2 16,888,317 $101,327,468 +$1,168,639 $6.00 75
2019 Q1 16,361,337 $147,746,642 -$6,160,793 $9.03 77
2018 Q4 17,157,946 $141,481,000 -$15,993,709 $8.30 75
2018 Q3 18,046,261 $248,653,190 +$81,737,278 $13.80 90
2018 Q2 12,131,183 $96,444,142 +$14,632,796 $7.95 65
2018 Q1 10,285,308 $77,138,000 +$3,821,299 $7.50 42
2017 Q4 9,777,889 $66,488,000 +$3,712,599 $6.80 35
2017 Q3 9,221,517 $66,394,000 +$13,267,111 $7.20 35
2017 Q2 7,437,286 $34,736,000 -$2,554,099 $4.65 24
2017 Q1 7,897,813 $37,958,000 +$8,366,763 $5.00 24
2016 Q4 6,136,618 $32,831,000 +$111,606 $5.35 20
2016 Q3 6,112,780 $47,882,100 -$1,304,703 $7.82 22
2016 Q2 6,358,443 $36,177,450 +$11,374,826 $5.69 25
2016 Q1 4,372,667 $18,317,243 -$231,292 $4.19 26
2015 Q4 4,427,755 $30,018,000 +$376,484 $6.78 20
2015 Q3 4,330,050 $25,241,000 +$608,221 $5.83 22
2015 Q2 4,225,512 $32,853,000 +$19,634,402 $7.76 23
2015 Q1 1,691,795 $17,415,000 +$8,386,368 $10.18 15
2014 Q4 870,129 $6,277,000 +$82,000 $7.18 5
2014 Q3 859,337 $5,163,000 +$34,237 $5.74 6
2014 Q2 852,047 $5,639,000 +$5,638,000 $6.56 5